How to do market research on diabetes, who has a market report on diabetes! It s very urgent...

China Industry Research Report Network News: Abstract: During the "Twelfth Five-Year Plan" period, China has formulated a series of pharmaceutical industry policies to support China's pharmaceutical enterprises and the Chinese medicine industry to become bigger and stronger, Tonghua Dongbao, Yangtze River Pharmaceutical, Zhongxin Pharmaceutical, Hengrui Pharmaceutical and other enterprises with core competitiveness in China will increase their market share in the diabetes drug industry.

Due to China's long-term poverty and backwardness, diabetes did not pose a huge threat to the health and life of our people in the past. In the past 20 years, China's national economy has developed rapidly, people's living standards have improved rapidly, and China's disease spectrum has undergone major changes, and chronic non-communicable diseases, including diabetes, have gradually become important social health problems. According to the data of 1996, the number of patients with diabetes and impaired glucose tolerance in China accounted for the total number of people over 20 years old, that is, the population with abnormal blood sugar was close to 100 million, and the incidence of diabetes in China in 2011 has reached 92.4 million, an increase from 2007.

The number of diabetic patients in China is on the rise. It is expected to reach 100 million in 2025. At present, Western medicine and foreign-funded companies still occupy a dominant position in the field of diabetes drugs in China.

Although China's domestic enterprises have developed greatly, many enterprises do not have core competitiveness, mainly generic drugs. Foreign pharmaceutical companies such as Bayer and Pfizer occupy a dominant position in this industry. During the "Twelfth Five-Year Plan" period, China has formulated a series of pharmaceutical industry policies to support China's pharmaceutical enterprises and the Chinese medicine industry to become bigger and stronger, and Tonghua Dongbao, Yangtze River Pharmaceutical, Zhongxin Pharmaceutical, Hengrui Pharmaceutical and other enterprises with core competitiveness in China will increase their market share in the diabetes drug industry.

China Industry Research Report Network (

The latest release of the "2012-2016 Diabetes Drug Industry Market Supply and Demand Analysis and Investment Direction Research and Consulting Report" pointed out that China's diabetes mainly includes Western medicine and Chinese patent medicine, of which Western medicine dominates diabetes, and Chinese patent medicine is in an auxiliary position in diabetes. With the increase in the prevalence of diabetes, the improvement of people's living standards and the improvement of medical standards, the scale of China's diabetes drug market has expanded year by year, and the data show that the scale of China's diabetes drug market has increased from 100 million yuan in 2002 to 100 million yuan in 2010. It is estimated that in 2013, the sales of China's diabetes drug market are expected to exceed 15 billion yuan.

By 2015, the market size of diabetes drugs will be close to 100 million yuan. You can log on to the China Industry Research Report website.

There are two common problems: 1. Hospitals, which are suitable for specific patients to understand the efficacy of the product and other survey content. 2. Sampling, suitable for conducting general survey interviews.

What's the problem, that there is such an investigation? Top.

For many pharmaceutical manufacturers, overcoming diabetes as soon as possible is not only the trend of their social responsibility, but also the need for them to obtain huge economic benefits.

1. Diabetes has become a global health concern.

The total number of people living with diabetes in the world has exceeded 100 million. India, China, and the United States are the three countries with the largest number of diabetic patients in the world today, mainly because of the large population and large base, and because of the high incidence of diabetes. These three countries are also the regions with the largest number of diabetes research institutions and the highest level of research in the world.

2. The last decade has been the fastest growing decade in the number of diabetic patients in China.

The prevalence of diabetes among Chinese residents has reached 31 million. Among them, the prevalence of diabetes among residents aged 20 to 74 has been reached, with an average net increase of more than 1.5 million per year.

3. Characteristics of the prevalence of diabetes mellitus among Chinese residents.

1. Regional differences.

2. Differences between urban and rural areas.

3. Gender differences.

4. Age differences.

5. Differences in education level.

6. Occupational differences.

4. Investigation of the death of diabetic patients in China.

The mortality rate in women with diabetes is significantly higher than in men. In recent years, the male-to-female mortality ratio of urban residents in China is 1:, and the male-to-female mortality ratio of rural residents is 1:, and the male-to-female mortality ratio of rural residents is 1:.

5. Diagnosis and treatment of diabetic patients in China.

1. Diagnosis and ** situation.

According to a survey in Guangdong, 70% of diabetes was first detected in a special survey. That is, only 30% of diabetic patients in China have been diagnosed, and among the 30 million diabetic patients, only less than 10 million people have been diagnosed, while another 20 million people who have actually been plagued by diabetes are not aware or have not been discovered, and according to expert estimates, only about 40% of the diabetic patients are diagnosed, that is, 4 million people are insisting on taking medicine**, and the average annual cost of drugs per person is about 1,600 yuan. The total theoretical market capacity of diabetes medication in China is 6.4 billion yuan.

2. Hospitalization. Lead matching.

The total number of diabetic patients in China is as high as more than 30 million, but the total number of hospitalizations per year is less than 300,000, that is, only 1% of the hospitalization rate, which shows that the hospitalization rate of such patients is not high, reflecting its major characteristics as a chronic disease. In the past decade, the total number of diabetes cases in urban hospitals in China has been gradually increasing, especially in the past two years, with the fastest growth. Experts believe that the total annual cost of hospitalization for urban diabetic patients is about 5,000 yuan, and this part of the patient can form a market capacity of 100 million yuan per year; Compared with urban hospitals, the number of cases in county-level hospitals is significantly less, and has been hovering between 20,000 and 40,000 cases for ten years, according to relevant experts' estimates, the cost of hospitalization for rural patients is relatively low, no more than 3,000 yuan per person per year, and this part of the patient can form a market capacity of 100 million yuan per year.